Most healthcare executives have an AI strategy but only half have implemented it

An overwhelming majority of healthcare executives have an artificial intelligence strategy but only 44% have put it into action, according to new survey results.

Optum queried more than 500 senior health execs from top hospitals, health plans, employers and other companies for the findings of its fourth annual survey.

Overall, 85% have an AI strategy but even more execs (89%) believe using such technology requires partnering with companies specialized in the data and analytics side of the industry.

Additionally, 96% say AI is a key part of achieving health equity goals while most (94%) agreed that institutions are responsible for ensuring artificial intelligence is used appropriately.

“The responsible use of AI continues to provide important opportunities for healthcare leaders to streamline administrative processes and provide more effective patient care with enhanced experiences for both patients and providers,” Steve Griffiths, senior vice president of data and analytics at Optum Labs, a research arm of UnitedHealth Group, said Dec. 15. “These leaders are not just users of AI, but they have an opportunity to be looked to as role models across industries in their commitment to using AI responsibly.”

The responses reveal that executives see nonclinical tasks as ripe for AI disruption. In fact, almost 3 of 4 leaders said they trust AI to support administrative work, allowing providers to focus on patients.

In terms of individual patients, 41% of respondents are excited about the potential for virtual care, while 40% said the same for AI in improving diagnoses and predicting outcomes. A separate 36% see artificial intelligence tools benefiting medical image interpretations.

“This year’s survey findings continue to validate how the responsible use of AI can help health systems strengthen and scale essential functions and reduce administrative burdens, all of which helps clinicians focus on their core mission of patient care,” said Rick Hardy, CEO of Optum Insight. “We share their enthusiasm for AI, but more importantly, we look forward to combining our healthcare expertise with AI to help people—patients, physicians, and those working behind the scenes—as that is where the real value is delivered.”

Download the report for free here.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.